Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.
Where this comes from
- Record sourced from PubMed, PMID 33395336.
- Also identified by DOI 10.7326/ACPJ202101190-010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bonaca MP, Wiviott SD, Zelniker TA, et al. <b>Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58.</b> Circulation. 2020;142:734-47. 32795086.
Medical subject headings
- Diabetes Mellitus, Type 2
- Peripheral Arterial Disease
- Sodium-Glucose Transporter 2 Inhibitors